Some existing data showed that the proportion of STK11 mutations in NSCLC is about 5–30% (28), and the proportion of patients with advanced or metastatic NSCLC may be higher (29, 30), demonstrating that STK11 mutation might probably be a late event in the evolvement of carcinogenesis in lung cancer. This evidence concerns the gene STK11 and lung carcinoma.